Harry Wilton-Clark

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Duchenne Muscular Dystrophy

Clinical Practice

Mesenchymal Stem Cells

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes 15 (7) (2024)
Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes 15 (7) (2024)
Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes 15 (7) (2024)
Harry Wilton-Clark, Toshifumi Yokota
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics 15 (3) (2023)
Harry Wilton-Clark, Ammar Al-Aghbari, Jessica Yang, Toshifumi Yokota
Advancing Epidemiology and Genetic Approaches for the Treatment of Spinal and Bulbar Muscular Atrophy: Focus on Prevalence in the Indigenous Population of Western Canada. Genes 14 (8) (2023)
Harry Wilton-Clark, Toshifumi Yokota
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics 15 (3) (2023)
Harry Wilton-Clark, Toshifumi Yokota
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics 15 (3) (2023)
Harry Wilton-Clark, Toshifumi Yokota
Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot. Genes 13 (2) (2022)